AU2014205529B2 - Methods and compositions for treatment of demyelinating diseases - Google Patents
Methods and compositions for treatment of demyelinating diseases Download PDFInfo
- Publication number
- AU2014205529B2 AU2014205529B2 AU2014205529A AU2014205529A AU2014205529B2 AU 2014205529 B2 AU2014205529 B2 AU 2014205529B2 AU 2014205529 A AU2014205529 A AU 2014205529A AU 2014205529 A AU2014205529 A AU 2014205529A AU 2014205529 B2 AU2014205529 B2 AU 2014205529B2
- Authority
- AU
- Australia
- Prior art keywords
- fingolimod
- mgbg
- pct
- recited
- mpk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000016192 Demyelinating disease Diseases 0.000 title claims abstract 3
- 238000000034 method Methods 0.000 title claims 11
- 239000000203 mixture Substances 0.000 title 1
- 239000008203 oral pharmaceutical composition Substances 0.000 claims abstract 8
- 229960000556 fingolimod Drugs 0.000 claims 24
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 24
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 claims 21
- 229960003539 mitoguazone Drugs 0.000 claims 21
- 239000000902 placebo Substances 0.000 claims 7
- 229940068196 placebo Drugs 0.000 claims 7
- 101100402341 Caenorhabditis elegans mpk-1 gene Proteins 0.000 claims 6
- 241000699670 Mus sp. Species 0.000 claims 6
- 206010053395 Progressive multiple sclerosis Diseases 0.000 claims 3
- 239000003981 vehicle Substances 0.000 claims 3
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 2
- 238000002649 immunization Methods 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 206010012305 Demyelination Diseases 0.000 claims 1
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims 1
- 102100022297 Integrin alpha-X Human genes 0.000 claims 1
- 102100033461 Interleukin-17A Human genes 0.000 claims 1
- LUWJPTVQOMUZLW-UHFFFAOYSA-N Luxol fast blue MBS Chemical compound [Cu++].Cc1ccccc1N\C(N)=N\c1ccccc1C.Cc1ccccc1N\C(N)=N\c1ccccc1C.OS(=O)(=O)c1cccc2c3nc(nc4nc([n-]c5[n-]c(nc6nc(n3)c3ccccc63)c3c(cccc53)S(O)(=O)=O)c3ccccc43)c12 LUWJPTVQOMUZLW-UHFFFAOYSA-N 0.000 claims 1
- 210000004322 M2 macrophage Anatomy 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 210000000068 Th17 cell Anatomy 0.000 claims 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000030741 antigen processing and presentation Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000003690 classically activated macrophage Anatomy 0.000 claims 1
- 230000001186 cumulative effect Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims 1
- 229960004419 dimethyl fumarate Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960003776 glatiramer acetate Drugs 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims 1
- 229960004577 laquinimod Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- -1 natalizumab Chemical compound 0.000 claims 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 claims 1
- 229960000331 teriflunomide Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract 2
- 229920000768 polyamine Polymers 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102100035914 S-adenosylmethionine decarboxylase proenzyme Human genes 0.000 abstract 1
- 108050004491 S-adenosylmethionine decarboxylase proenzyme Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 230000008094 contradictory effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018247351A AU2018247351B2 (en) | 2013-01-08 | 2018-10-15 | Methods and compositions for treatment of demyelinating diseases |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750336P | 2013-01-08 | 2013-01-08 | |
| US61/750,336 | 2013-01-08 | ||
| US201361823276P | 2013-05-14 | 2013-05-14 | |
| US61/823,276 | 2013-05-14 | ||
| PCT/US2014/010714 WO2014110154A1 (en) | 2013-01-08 | 2014-01-08 | Methods and comp0stions for treatment of demyelinating diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018247351A Division AU2018247351B2 (en) | 2013-01-08 | 2018-10-15 | Methods and compositions for treatment of demyelinating diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014205529A1 AU2014205529A1 (en) | 2015-07-09 |
| AU2014205529B2 true AU2014205529B2 (en) | 2018-08-09 |
Family
ID=51167347
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014205529A Ceased AU2014205529B2 (en) | 2013-01-08 | 2014-01-08 | Methods and compositions for treatment of demyelinating diseases |
| AU2018247351A Ceased AU2018247351B2 (en) | 2013-01-08 | 2018-10-15 | Methods and compositions for treatment of demyelinating diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018247351A Ceased AU2018247351B2 (en) | 2013-01-08 | 2018-10-15 | Methods and compositions for treatment of demyelinating diseases |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10085955B2 (enExample) |
| EP (2) | EP3831372A1 (enExample) |
| JP (2) | JP6370804B2 (enExample) |
| CN (2) | CN109432073A (enExample) |
| AU (2) | AU2014205529B2 (enExample) |
| BR (1) | BR112015016189A8 (enExample) |
| CA (1) | CA2896977C (enExample) |
| DK (1) | DK2943189T3 (enExample) |
| ES (1) | ES2859553T3 (enExample) |
| IL (1) | IL239851B (enExample) |
| WO (1) | WO2014110154A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE033487T2 (en) | 2007-03-09 | 2017-12-28 | Pathologica Llc | MGBG for osteopontin control and multiple sclerosis treatment |
| CN102686222B (zh) | 2009-07-16 | 2015-06-24 | 帕萨罗杰卡有限公司 | 包含mgbg的口服递送药物以及治疗疾病的方法 |
| US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
| DK2665471T3 (en) | 2011-01-19 | 2018-03-19 | Pathologica Llc | ORAL PHARMACEUTICAL DOSAGE FORMS WITH MANAGED RELEASE COMPREHENSIVE MGBG |
| CA2896977C (en) | 2013-01-08 | 2021-12-07 | Pathologica Llc | Methods and compositions for treatment of demyelinating diseases |
| US20160058730A1 (en) * | 2014-08-29 | 2016-03-03 | Cadila Healthcare Limited | Pharmaceutical compositions of teriflunomide |
| MA41785A (fr) | 2015-03-20 | 2018-01-23 | Biogen Ma Inc | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
| EP3118621A1 (en) * | 2015-07-14 | 2017-01-18 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy |
| EP3347017A1 (en) * | 2015-09-08 | 2018-07-18 | Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin | Quinoline derivates for use in treating leukodystrophy and treatment method |
| JP6750820B2 (ja) * | 2016-03-07 | 2020-09-02 | 国立大学法人大阪大学 | 神経損傷治療用薬剤徐放シート |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| LT3506921T (lt) | 2016-08-31 | 2023-08-10 | Mapi Pharma Ltd | Ilgesnio atpalaidavimo sistemos, kuriose yra glatiramero acetato |
| BR112019017724A2 (pt) | 2017-03-26 | 2020-03-31 | Mapi Pharma Ltd. | Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla |
| AU2019253059A1 (en) * | 2018-04-13 | 2020-11-12 | Mordechai Chevion | Compositions and methods for treatment of demyelination |
| CN114845718B (zh) * | 2019-12-19 | 2025-05-16 | 活跃生物技术有限公司 | 用于治疗与过度血管形成相关的眼部疾病的化合物 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4201788A (en) | 1976-10-20 | 1980-05-06 | University Patents, Inc. | Process for alleviating proliferative skin diseases |
| US5614557A (en) | 1977-07-11 | 1997-03-25 | Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. | Method of controlling tumor growth rate |
| US4520031A (en) | 1981-06-01 | 1985-05-28 | The United States Of America As Represented By The Secretary Of Department Of Health And Human Services | Method for reducing toxic effects of methyl-glyoxal bis-guanylhydrazone |
| US5580715A (en) | 1994-08-05 | 1996-12-03 | The Regents Of The University Of California | Diagnosis of cancer having clonal macrophage involvement |
| US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
| US5698563A (en) | 1995-01-13 | 1997-12-16 | Alteon Inc. | Bis- hydrazones! |
| EP1459744A3 (en) | 1996-09-13 | 2004-12-15 | University Of Florida Research Foundation, Inc. | Method of inhibiting biosynthesis of elf5a |
| AR009380A1 (es) | 1996-10-21 | 2000-04-12 | Sumitomo Chemical Co | Proceso de preparacion de un derivado de piridazin-3-ona, util como herbicida, acido carboxilico de utilizacion en el mismo, sal de este ultimo y proceso para preparar dicho acido carboxilico |
| US6083496A (en) | 1996-10-22 | 2000-07-04 | Universite Laval | Polyamine transport inhibitors |
| JP4044728B2 (ja) | 1997-07-15 | 2008-02-06 | メディクエスト セラピューティックス インク | 治療および診断薬剤としての新規なポリアミンアナログ |
| US5889061A (en) | 1997-10-15 | 1999-03-30 | Wisconsin Alumni Research Foundation | Conformationally restricted polyamines |
| US8198334B2 (en) | 1997-10-27 | 2012-06-12 | Pathologica Llc | Methods for modulating macrophage proliferation in ocular disease using polyamine analogs |
| US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
| US6169115B1 (en) | 1998-05-22 | 2001-01-02 | Rima Kaddurah-Daouk | Use of aminoguanidine analogs for the treatment of diseases of the nervous system |
| NZ515140A (en) | 1999-04-30 | 2003-07-25 | Slil Biomedical Corp | Conformationally restricted polyamine analogs as disease therapies for cancer, epilepsy, alzheimers, infections, grafts and others |
| US6544541B1 (en) * | 1999-06-02 | 2003-04-08 | Cardiovascular Solutions, Inc. | Devices and compounds for treating arterial restenosis |
| WO2001060392A1 (en) | 2000-02-18 | 2001-08-23 | Yeda Research And Development Co., Ltd. At The Weizmann Institute Of Science | Oral, nasal and pulmonary dosage formualtions of copolymer 1 |
| AU2002235126A1 (en) | 2000-11-08 | 2002-05-21 | Slil Biomedical Corporation | Novel polyamine analog-amino acid conjugates useful as anticancer agents |
| US7754765B2 (en) | 2000-12-01 | 2010-07-13 | Radical Vision Therapeutics Inc | Copper chelators for treating ocular inflammation |
| US6963010B2 (en) | 2001-01-08 | 2005-11-08 | Mediquest Therapeutics, Inc. | Hydrophobic polyamine analogs and methods for their use |
| CA2456034A1 (en) | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
| US7045550B2 (en) | 2001-08-07 | 2006-05-16 | Wisconsin Alumni Research Foundation | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy |
| US6924095B2 (en) | 2001-08-15 | 2005-08-02 | The Regents Of The University Of California | Retrovirus isolated from mantle histiocytes in mantle cell lymphoma |
| US7030126B2 (en) | 2001-11-16 | 2006-04-18 | Als Therapy Development Foundation, Inc. | Use of polyamine analogs for amyotrophic lateral sclerosis |
| JP2005519033A (ja) * | 2001-11-21 | 2005-06-30 | ザ ボード オブ トラスティーズ オブ レランド スタンフォード ジュニア ユニバーシティ | オステオポンチン関連組成物および方法 |
| US7622117B2 (en) | 2002-04-17 | 2009-11-24 | Dynamis Therapeutics, Inc. | 3-deoxyglucosone and skin |
| EP1389480A1 (en) | 2002-08-14 | 2004-02-18 | Mondobiotech Interferon SA | Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation |
| WO2004069174A2 (en) | 2003-01-31 | 2004-08-19 | Slil Biomedical Corporation | Monitoring and treatment of amyotrophic lateral sclerosis |
| HRP20100600A2 (hr) | 2003-04-08 | 2011-03-31 | Novartis Ag | Kruti farmaceutski pripravci koji sadrže agonist s1p receptora i šećerni alkohol |
| US20050042277A1 (en) | 2003-07-17 | 2005-02-24 | Irukulla Srinivas | Pharmaceutical compositions having a swellable coating |
| US20050025825A1 (en) | 2003-07-31 | 2005-02-03 | Xanodyne Pharmacal, Inc. | Tranexamic acid formulations with reduced adverse effects |
| WO2005041988A1 (en) | 2003-10-22 | 2005-05-12 | University Of Florida | Method and composition for pain amelioration |
| WO2005105729A1 (en) | 2004-02-13 | 2005-11-10 | Mediquest Therapeutics, Inc. | Polyamine analogs that activate antizyme frameshifting |
| US7445794B1 (en) | 2004-04-29 | 2008-11-04 | The Regents Of The University Of Colorado | Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors |
| US20060189546A1 (en) | 2005-01-28 | 2006-08-24 | Ajami Alfred M | Compounds for treating autoimmune and demyelinating diseases |
| AU2006275679B2 (en) | 2005-07-29 | 2012-04-12 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of Chk2 kinase inhibitors for cancer treatment |
| EP1916995B2 (en) | 2005-07-29 | 2022-06-29 | Stichting Groningen Centre for Drug Research | Ph-controlled pulsatile delivery system, methods for preparation and use thereof |
| EP1937235B1 (en) | 2005-09-23 | 2015-07-01 | Pathologica, LLC. | Methods for treating viral infections using polyamine analogs |
| WO2007040535A1 (en) | 2005-10-03 | 2007-04-12 | Cellgate, Inc. | Use of polyamine analogs for treatment and prevention of intestinal polyps |
| US20110091418A1 (en) | 2006-09-25 | 2011-04-21 | Pathlogica, LLC | Methods for treating viral infections using polyamine analogs |
| JP4929505B2 (ja) | 2006-10-31 | 2012-05-09 | Ｉｄｅｃ株式会社 | リレーソケット |
| HUE033487T2 (en) | 2007-03-09 | 2017-12-28 | Pathologica Llc | MGBG for osteopontin control and multiple sclerosis treatment |
| EP2164698A1 (en) | 2007-03-09 | 2010-03-24 | Sustainable Solutions, Inc. | Regenerated cotton board material and method of manufacture |
| WO2008112251A1 (en) | 2007-03-14 | 2008-09-18 | Progen Pharmaceuticals, Inc. | Cyclopropyl-containing polyamine analogs as disease therapies |
| WO2009018368A1 (en) | 2007-07-30 | 2009-02-05 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders |
| WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| JP2012505257A (ja) | 2008-10-13 | 2012-03-01 | バイオヴィスタ，インコーポレイテッド | 多発性硬化症治療のための組成物および方法 |
| US9498431B2 (en) | 2008-12-10 | 2016-11-22 | Jianjian Xu | Controlled releasing composition |
| US20100189788A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline base formulation |
| US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
| CN102686222B (zh) | 2009-07-16 | 2015-06-24 | 帕萨罗杰卡有限公司 | 包含mgbg的口服递送药物以及治疗疾病的方法 |
| EP2283830A1 (en) | 2009-07-23 | 2011-02-16 | Actogenix N.V. | Aqueous enteric capsule coating |
| EP2343075A1 (en) | 2010-01-04 | 2011-07-13 | Neurotec Pharma, S.L. | Diazoxide for use in the treatment a central nervous system (CNS) autoimmune demyelinating disease |
| TWI590821B (zh) | 2011-01-18 | 2017-07-11 | 輝瑞有限公司 | 固體分子分散液 |
| DK2665471T3 (en) | 2011-01-19 | 2018-03-19 | Pathologica Llc | ORAL PHARMACEUTICAL DOSAGE FORMS WITH MANAGED RELEASE COMPREHENSIVE MGBG |
| DK2675893T3 (en) * | 2011-02-18 | 2019-04-15 | Scripps Research Inst | Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate |
| CA2896977C (en) | 2013-01-08 | 2021-12-07 | Pathologica Llc | Methods and compositions for treatment of demyelinating diseases |
-
2014
- 2014-01-08 CA CA2896977A patent/CA2896977C/en active Active
- 2014-01-08 JP JP2015551862A patent/JP6370804B2/ja not_active Expired - Fee Related
- 2014-01-08 AU AU2014205529A patent/AU2014205529B2/en not_active Ceased
- 2014-01-08 WO PCT/US2014/010714 patent/WO2014110154A1/en not_active Ceased
- 2014-01-08 BR BR112015016189A patent/BR112015016189A8/pt not_active Application Discontinuation
- 2014-01-08 CN CN201811424556.8A patent/CN109432073A/zh active Pending
- 2014-01-08 CN CN201480007129.3A patent/CN105163730B/zh not_active Expired - Fee Related
- 2014-01-08 EP EP21152182.8A patent/EP3831372A1/en not_active Withdrawn
- 2014-01-08 ES ES14737914T patent/ES2859553T3/es active Active
- 2014-01-08 EP EP14737914.3A patent/EP2943189B1/en active Active
- 2014-01-08 US US14/759,599 patent/US10085955B2/en active Active
- 2014-01-08 DK DK14737914.3T patent/DK2943189T3/da active
-
2015
- 2015-07-08 IL IL239851A patent/IL239851B/en active IP Right Grant
-
2018
- 2018-07-10 JP JP2018130715A patent/JP2018172427A/ja active Pending
- 2018-08-23 US US16/109,824 patent/US10350178B2/en not_active Expired - Fee Related
- 2018-10-15 AU AU2018247351A patent/AU2018247351B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3831372A1 (en) | 2021-06-09 |
| WO2014110154A1 (en) | 2014-07-17 |
| CN105163730B (zh) | 2018-10-30 |
| CN109432073A (zh) | 2019-03-08 |
| AU2018247351A1 (en) | 2018-11-08 |
| AU2014205529A1 (en) | 2015-07-09 |
| US10350178B2 (en) | 2019-07-16 |
| JP6370804B2 (ja) | 2018-08-08 |
| ES2859553T3 (es) | 2021-10-04 |
| JP2018172427A (ja) | 2018-11-08 |
| NZ709157A (en) | 2020-09-25 |
| NZ749754A (en) | 2020-09-25 |
| AU2018247351B2 (en) | 2020-04-09 |
| US20150359761A1 (en) | 2015-12-17 |
| US20180360783A1 (en) | 2018-12-20 |
| US10085955B2 (en) | 2018-10-02 |
| HK1217451A1 (en) | 2017-01-13 |
| EP2943189A1 (en) | 2015-11-18 |
| DK2943189T3 (da) | 2021-04-06 |
| IL239851A0 (en) | 2015-08-31 |
| BR112015016189A8 (pt) | 2019-10-22 |
| CN105163730A (zh) | 2015-12-16 |
| EP2943189A4 (en) | 2016-07-06 |
| JP2016504389A (ja) | 2016-02-12 |
| EP2943189B1 (en) | 2021-03-10 |
| CA2896977C (en) | 2021-12-07 |
| BR112015016189A2 (pt) | 2017-07-11 |
| CA2896977A1 (en) | 2014-07-17 |
| IL239851B (en) | 2020-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014205529B2 (en) | Methods and compositions for treatment of demyelinating diseases | |
| US11207279B2 (en) | Application of R-ketamine and salt thereof as pharmaceuticals | |
| WO2013022783A3 (en) | Progesterone containing oral dosage forms and related methods | |
| CY1123006T1 (el) | Διασπειρομενη στο στομα δοσολογικη μοναδα η οποια περιεχει ενα συστατικο οιστετρολης | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| PH12014500472A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| AU2012286851A8 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| WO2011160136A3 (en) | Progesterone containing oral dosage forms and related methods | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| TN2016000230A1 (en) | Orally disintegrating solid dosage unit containing an estetrol component. | |
| EA201201403A1 (ru) | Очень низкодозированные твердые пероральные лекарственные формы для гзт | |
| PH12017502049A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2020503269A5 (enExample) | ||
| NZ737948A (en) | Orodispersible dosage unit containing an estetrol component | |
| RU2018103940A (ru) | Фармацевтические композиции, содержащие антагонист интегрина альфа4, для применения в лечении воспалительных состояний глаза | |
| JP2020500864A5 (enExample) | ||
| PH12013500173A1 (en) | Oral controlled release pharmaceutical compositions of blonanserin | |
| JP2010514834A5 (enExample) | ||
| JP2016512247A5 (enExample) | ||
| JP2019507786A5 (enExample) | ||
| JP2019531286A5 (enExample) | ||
| JP2015521647A5 (enExample) | ||
| HK1200331A1 (en) | Improving postural stability administering droxidopa | |
| ZA202204907B (en) | Orally disintegrating pharmaceutical compositions of apixaban | |
| MX2015010594A (es) | Esteres de testosterona de cadena larga lipobalanceados para suministro oral. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |